Michael D Dake (Tucson, USA) presented results from the VERNACULAR trial, which was designed to assess the performance of the Venovo venous stent (BD) for the treatment of iliac and femoral vein occlusions. At one year, the researchers found that the overall patency rate was more than 88%. Importantly, beyond patency data, patients in the trial reported a statistically significant clinical improvement in their pain and quality of life scores over baseline from immediately after the procedure out to one year.
